In the second post of our ‘Kick Start your Healthcare Reorganisation’ series we focus on the implementation phase of a healthcare and life sciences reorganisation and specifically the following three areas: Whilst each area is individually significant, and is likely to have its own dedicated workstream, it is important to recognise that they each go hand in hand when looking to achieve smooth (and successful) implementation. Document execution First, on multi-jurisdictional projects, with a large…
OGYÉI’s integration into the new authority As of 1 August 2023, the National Institute of Pharmacy and Nutrition (OGYÉI) shall be merged into the National Public Health Center. The new authority will be called the National Center for Public Health and Pharmacy (NNGYK). The new authority will be headed by the Chief Medical Officer, and in terms of administrative hierarchy, the NNGYK will be under the supervision of the Minister of the Interior, acting in the…
On 25 July 2023, the EU Commission published its response to the European Citizens’ Initiative’s petition on “Save Cruelty-free Cosmetics – Commit to a Europe without Animal Testing”. The petition received 1.2 million signatures from EU citizens and the EU Commission must respond to petitions gathering 1 million signatures or more. The EU Commission has confirmed the following in response to the requests of the petition: Protect and strengthen the cosmetics animal testing ban Transform…
Last month, the UK House of Commons debated the current state of regulatory and legal hurdles negatively affecting the development of psilocybin-based (the psychedelic compound most commonly found in ‘magic mushrooms’) therapies for mental and physical health disorders in the UK. The debate resulted from an e-petition, which garnered 11,824 votes in February this year. The debate saw a consensus among Members of Parliament across party lines, collectively supporting the proposal for rescheduling psilocybin from…
In the first post of our ‘Kick Start your Healthcare Reorganisation’ series we focus on the planning phase of a reorganisation in the healthcare and life sciences sector in the context of spin offs, carve outs and other solvent group restructurings. It goes without saying that when preparing for a large reorganisation there is a significant amount of planning required to ensure seamless transition and continuity of supply chain. The industry is heavily regulated which…
Undertaking large, complex corporate reorganisation projects, such as spin offs, carve outs and other solvent group restructurings, always presents challenges to be considered, planned for and overcome. Some of those challenges are inherent to reorganisations in general but there are also those which stem from particular industry factors. Over the next three weeks, we will be focusing on the healthcare and life sciences industry and will, through a series of posts, highlight key considerations at…
HM Treasury (HMT) has launched a consultation seeking views on the design of a single, simplified research and development (R&D) tax relief scheme, merging the existing R&D expenditure credit (RDEC) and the small and medium enterprise (SME) R&D relief into an RDEC-like scheme. The new scheme, if implemented, would apply in respect of expenditure incurred from 1 April 2024. The integration of the existing schemes with a single approach may have a decisive impact on the future…
In brief On 1 December 2022, Switzerland’s new Human Genetic Testing Act (HGTA) will enter into force. The new HGTA provides a comprehensive legal framework for all types of genetic testing (including direct-to-consumer genetic testing and lifestyle genetic testing) and implements stronger measures to protect privacy rights, prevent abuse of genetic data and ensure the quality of genetic tests and the interpretation of the results. As part of the comprehensive revision of the HGTA, the…
In brief In a draft compromise text obtained by Politico, the European Council has dropped a key provision seeking to harmonise telemedicine from the draft European Health Data Space (EHDS). The (now-removed) Article 8 was aimed at encouraging the cross-border provision of telemedicine services across the EU. However, the reality is that there are vast national differences between Member States on telemedicine-related laws. It is going to require a far more concerted legislative effort to harmonise this area…